. /.  WORLD TRADE  
ORGANIZATION   
G/TBT/N/CAN/366 
25 June 2012  
 (12-3344) 
Committee on Technical Barriers to Trade Original:   English/ 
 French 
 
 
 
NOTIFICATION 
 
The following notification is being circ ulated in accordance with Article 10.6 
 
1. Notifying Member:  CANADA  
If applicable, name of local governme nt involved (Article 3.2 and 7.2):     
2. Agency responsible:  Department of Health 
Name and address (including telephone and fax numbers, email and website 
addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above :  Canadian Enquiry 
Point, 200-270 Albert Street, Ottawa, Ontari o, Canada, K1P 6N7 Tel.:  +1 613 238 3222, 
Fax.:  +1 613 569 7808, E-mail:  enquirypoint@scc.ca  
3. Notified under Article 2.9.2 [X], 2.10.1 [   ], 5.6.2 [   ], 5.7.1 [   ], other:   
4. Products covered (HS or CCCN where applicable, otherwise national tariff heading. 
ICS numbers may be provided in addition, where applicable):  Synthetic Drug 
(ICS: 71.060) 
5. Title, number of pages and language(s) of the notified document:  Notice to interested 
parties - Proposed amendment to Schedule I to  the Controlled Drug s and Substances Act 
(2 pages, in English and French).     
6. Description of content:  This notice provides interested stak eholders with the opportunity to 
provide comments on Health Canada's intent to add methylenedioxy pyrovalerone (MDPV), 
namely 3,4-methylenedioxypyrovalerone and its salts, derivatives, isomers and analogues and 
salts of derivatives, isomers and analogues to Schedule I to the Controlled Drugs and 
Substances Act (CDSA). Methylenedioxypyrovalerone is a synthetic drug that is used for its 
stimulant-like psychoactive effects.  
Health Canada is proposing to include MDPV in  Schedule I to the CDSA in order to prohibit 
the following activities with this substance: poss ession, trafficking, possession for the purpose 
of trafficking, importation, e xportation, possession for the purpose of exportation, and 
production. The scheduling of MDPV will also ensure law enforcement can take action under 
the CDSA against all suspected illegal activities involving MDPV. 
7. Objective and rationale, including the na ture of urgent problems where applicable:  
Protection of human health and safety  
8. Relevant documents:   Canada Gazette , Part I, 9 June 2012, Pa ges 1483-1484 (Available in 
English and French)   G/TBT/N/CAN/366 
Page 2  
 
  9. Proposed date of adoption:   
Proposed date of entry into force:    Normally within 5 to 8 months of publication in 
the Canada Gazette , Part I. 
On the date the measure is adopted. 
10. Final date for comments:  9 July 2012 
11. Text available from:  National enquiry point [X], or address, telephone and fax 
numbers, e-mail and web-site addres ses, if available of the other body:   The electronic 
version of the regulatory text can be downloaded at:  
http://www.gazette.gc.ca/rp-pr/p1/ 2012/2012-06-09/pdf/g1-14623.pdf#page=9 ( Canada 
Gazette )  
or 
http://www.gazette.gc.ca/rp-pr/p1/2012/ 2012-06-09/html/notice-avis-eng.html#d106 
(English) 
http://www.gazette.gc.ca/rp-pr/p1/2012/2012-06-09/ html/notice-avis-fra.h tml#d106  (French)